215 related articles for article (PubMed ID: 37329384)
1. Advances in Osteosarcoma.
Panez-Toro I; Muñoz-García J; Vargas-Franco JW; Renodon-Cornière A; Heymann MF; Lézot F; Heymann D
Curr Osteoporos Rep; 2023 Aug; 21(4):330-343. PubMed ID: 37329384
[TBL] [Abstract][Full Text] [Related]
2. Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors.
Ratti C; Botti L; Cancila V; Galvan S; Torselli I; Garofalo C; Manara MC; Bongiovanni L; Valenti CF; Burocchi A; Parenza M; Cappetti B; Sangaletti S; Tripodo C; Scotlandi K; Colombo MP; Chiodoni C
Clin Cancer Res; 2017 Sep; 23(17):5149-5161. PubMed ID: 28600479
[No Abstract] [Full Text] [Related]
3. Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality.
Yu L; Zhang J; Li Y
Front Immunol; 2022; 13():871076. PubMed ID: 36311748
[TBL] [Abstract][Full Text] [Related]
4. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
5. Drugs in early clinical development for the treatment of osteosarcoma.
Heymann MF; Brown HK; Heymann D
Expert Opin Investig Drugs; 2016 Nov; 25(11):1265-1280. PubMed ID: 27633385
[TBL] [Abstract][Full Text] [Related]
6. The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.
Koshkina N; Yang Y; Kleinerman ES
Adv Exp Med Biol; 2020; 1258():177-187. PubMed ID: 32767242
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies.
Ying H; Li ZQ; Li MP; Liu WC
Front Endocrinol (Lausanne); 2023; 14():1217669. PubMed ID: 37497349
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma.
Yang H; Zhao L; Zhang Y; Li FF
Cancer Med; 2021 Aug; 10(16):5696-5711. PubMed ID: 34258887
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation.
Liu C; Wang M; Xu C; Li B; Chen J; Chen J; Wang Z
J Immunol Res; 2021; 2021():8970173. PubMed ID: 34877360
[TBL] [Abstract][Full Text] [Related]
11. Reduction of Lung Metastases in a Mouse Osteosarcoma Model Treated With Carbon Ions and Immune Checkpoint Inhibitors.
Helm A; Tinganelli W; Simoniello P; Kurosawa F; Fournier C; Shimokawa T; Durante M
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):594-602. PubMed ID: 32980497
[TBL] [Abstract][Full Text] [Related]
12. Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases.
Huang G; Nishimoto K; Yang Y; Kleinerman ES
Adv Exp Med Biol; 2014; 804():203-17. PubMed ID: 24924176
[TBL] [Abstract][Full Text] [Related]
13. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma cancer.
Liu R; Hu Y; Liu T; Wang Y
BMC Cancer; 2021 Dec; 21(1):1345. PubMed ID: 34922489
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential.
Wen Y; Tang F; Tu C; Hornicek F; Duan Z; Min L
Cancer Lett; 2022 Oct; 547():215887. PubMed ID: 35995141
[TBL] [Abstract][Full Text] [Related]
15. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.
Gordon N; Kleinerman ES
J Aerosol Med Pulm Drug Deliv; 2010 Aug; 23(4):189-96. PubMed ID: 20528149
[TBL] [Abstract][Full Text] [Related]
16. Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases.
Lamora A; Mullard M; Amiaud J; Brion R; Heymann D; Redini F; Verrecchia F
Oncotarget; 2015 Jun; 6(16):14413-27. PubMed ID: 26015407
[TBL] [Abstract][Full Text] [Related]
17. The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications.
Huang Q; Liang X; Ren T; Huang Y; Zhang H; Yu Y; Chen C; Wang W; Niu J; Lou J; Guo W
Cell Oncol (Dordr); 2021 Jun; 44(3):525-539. PubMed ID: 33788151
[TBL] [Abstract][Full Text] [Related]
18. Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma.
Guenther LM; Rowe RG; Acharya PT; Swenson DW; Meyer SC; Clinton CM; Guo D; Sridharan M; London WB; Grier HE; Ecklund K; Janeway KA
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29251406
[TBL] [Abstract][Full Text] [Related]
19. Osteosarcoma, personalized medicine, and tissue engineering; an overview of overlapping fields of research.
Bozorgi A; Sabouri L
Cancer Treat Res Commun; 2021; 27():100324. PubMed ID: 33517237
[TBL] [Abstract][Full Text] [Related]
20. Caffeine-potentiated chemotherapy for metastatic osteosarcoma.
Kimura H; Tsuchiya H; Shirai T; Nishida H; Hayashi K; Takeuchi A; Ohnari I; Tomita K
J Orthop Sci; 2009 Sep; 14(5):556-65. PubMed ID: 19802667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]